Core Viewpoint - Centene Corporation will release its 2025 second quarter financial results on July 25, 2025, at 6:00 a.m. ET, followed by a conference call at 8:00 a.m. ET to discuss the results [1]. Group 1: Financial Results Announcement - The financial results will be available for review on July 25, 2025, at approximately 6:00 a.m. ET [1]. - A conference call will be held at 8:00 a.m. ET on the same day to discuss the financial results [1]. Group 2: Conference Call Participation - Interested parties can join the conference call by dialing 1-877-883-0383 in the U.S. and Canada or +1-412-902-6506 from abroad, using the Elite Entry Number: 7878291 for expedited registration [2]. - The call can also be accessed via a live audio webcast on Centene's website under the Investors section [2]. Group 3: Webcast Replay Information - A replay of the webcast will be available for on-demand listening for 12 months, until July 24, 2026 [3]. - Digital audio playback will be accessible until August 1, 2025, by dialing specific numbers and entering access code 7322068 [3]. Group 4: Company Overview - Centene Corporation is a Fortune 500 company focused on providing integrated, high-quality, and cost-effective healthcare services, particularly to under-insured and uninsured individuals [4]. - The company serves over 1 in 15 individuals in the U.S., including Medicaid and Medicare members, as well as those in the Health Insurance Marketplace [4]. Group 5: Investor Relations - Centene utilizes its investor relations website to publish important information deemed material to investors [5]. - Financial and other relevant information about Centene is routinely posted and accessible on its investor relations website [5].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for alleged violations of securities laws, claiming the company made false and misleading statements regarding its growth and revenue forecasts [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between December 12, 2024, and June 30, 2025, during which investors are encouraged to contact the Schall Law Firm before September 8, 2025 [2]. - The complaint alleges that Centene misrepresented its ability to forecast growth and revenue, leading to a false impression of strong enrollment rates and low morbidity [4]. Group 2: Impact on Investors - The company's optimistic guidance was contradicted by an analysis revealing lower-than-expected enrollment and increased market morbidity, resulting in material misstatements throughout the class period [4]. - When the truth about Centene's performance became known, investors reportedly suffered damages [4].

Core Viewpoint - Centene's stock is currently trading at approximately 0.5 times its book value, presenting a significant investment opportunity [1] Group 1 - The market is providing an obvious opportunity with Centene, suggesting that the current valuation may be undervalued [1]

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Summary by Relevant Sections Allegations - The complaint alleges that Centene's management made overwhelmingly positive statements to investors while concealing material adverse facts about the company's true enrollment and morbidity rates [3]. - On July 1, 2025, Centene issued a press release withdrawing its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. Stock Performance - Following the announcement on July 1, 2025, Centene's stock price plummeted from $56.65 per share to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Class Action Details - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is September 8, 2025, and there is no cost or obligation to participate in the case [4]. Law Firm Information - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, about the September 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Centene common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - The lead plaintiff must file a motion with the Court by September 8, 2025, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Background - The lawsuit alleges that Centene's defendants provided misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [4] - Positive statements about Centene's enrollment and morbidity rates were made while concealing material adverse facts about the true state of these metrics [4]

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Centene Corporation ("Centene" or the "Company") (NYSE: CNC) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CENTENE CORPORATION (CNC), CLICK HERE BEFORE SEPTEMBER 8, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.What Is The Lawsuit About? The complaint filed alleges that, betwe ...

CONTACT US HERE: https://securitiesclasslaw.com/securities/centene-corporation-loss-submission-form/?id=157185&from=4 CLASS PERIOD: December 12, 2024 to June 30, 2025 NEW YORK, July 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centene Corporation (NYSE: CNC). ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or conceali ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to significant stock price declines [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Centene to contact them for legal options, particularly those who purchased securities between December 12, 2024, and June 30, 2025 [1][3]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Company Performance and Stock Impact - Centene provided positive statements to investors while concealing adverse facts about its enrollment and morbidity rates, leading to a significant loss of investor trust [5]. - On July 1, 2025, Centene withdrew its 2025 guidance, stating that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% in just one day [6].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. - Investors have until September 8, 2025, to request to lead the case [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated lower than expected market growth and higher morbidity rates, leading to a stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - The Centene class action lawsuit alleges that Centene Corporation and its executives misled investors regarding the company's revenue outlook and growth potential, leading to significant financial losses for shareholders [4][5]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, seeks to represent purchasers of Centene securities and claims violations of the Securities Exchange Act of 1934 [1]. - Centene is accused of creating a false impression of reliable revenue projections and growth while actual enrollment rates and market morbidity were lower than anticipated [4]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, resulting in a significant stock price drop of over 40% [5]. Group 2: Financial Impact - The preliminary analysis indicated that Centene's guidance was reduced to approximately $1.8 billion, with an adjusted diluted EPS of $2.75 [5]. - The lawsuit highlights that over two-thirds of Centene's marketplace share showed disappointing enrollment figures, contradicting the company's earlier optimistic reports [4]. Group 3: Legal Process - Investors who suffered losses can seek to become lead plaintiffs in the class action lawsuit, which allows them to represent the interests of all class members [6]. - The lead plaintiff can choose a law firm to litigate the case, and participation as a lead plaintiff does not affect the ability to share in any potential recovery [6]. Group 4: Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history of $7.2 billion in the Enron case [7].